October 9, 2026 · Science · Biomarkers
What the Suita Study Measured
The Suita Study investigated how circulating lipoprotein(a) concentrations related to new carotid plaque formation in Japanese adults. Researchers analyzed 3,272 participants who had no clinical cardiovascular disease and no carotid plaque at enrollment. Investigators performed repeated carotid ultrasound examinations every two years through June 2016 to monitor structural changes inside the arteries.
The cohort underwent a median follow-up period of 11.5 years, creating an extended observation window for Lp(a) and atherosclerosis. During this multi-year timeframe, 1,432 of the 3,272 enrolled participants developed a new carotid plaque. Teramoto and colleagues published their findings in the European Journal of Preventive Cardiology in 2026, which was subsequently reported by MedicalXpress.
To evaluate differences in disease trajectory, the study authors sorted participant biomarker results into four specific baseline categories. Those groupings included concentrations under 15 mg/dL, 15 to 29 mg/dL, 30 to 49 mg/dL, and 50 mg/dL or above. The group under 15 mg/dL served as the baseline reference comparison for all subsequent statistical calculations across the cohort.
The highest category represented a distinct minority of the total sample. About 5 percent of the 3,272 participants had baseline Lp(a) measurements at or above 50 mg/dL. The published coverage notes that the relationship between Lp(a) and carotid atherosclerosis progression had remained unclear in East Asian populations.
The short version
What a Result at or Above 50 mg/dL Tracked With
In 3,272 Japanese adults who started free of cardiovascular disease and carotid plaque, baseline Lp(a) at or above 50 mg/dL tracked with three distinct arterial outcomes. First, participants in the highest category showed a multivariable-adjusted hazard ratio of 1.27 for developing new carotid plaque compared with those under 15 mg/dL. The source does not publish a confidence interval for this hazard ratio, so the precise boundaries around the estimate remain unknown.
Second, individuals with lipoprotein(a) 50 mg/dL or higher experienced faster annual progression of carotid intima-media thickness. The study authors evaluated carotid intima-media thickness repeatedly during the biennial ultrasound evaluations. The published report does not provide a numeric effect size or millimeter measurement for this annual rate of change.
Third, among the subset of 1,432 participants who developed carotid plaque, the highest group faced more than twice the odds of developing severe stenosis. The researchers defined this advanced stage as arterial narrowing reaching 50 percent or greater carotid stenosis. The published coverage does not report an exact odds ratio or a confidence interval for this severe stenosis comparison.
These three findings together describe how arterial changes unfolded over the 11.5-year observation period. About 5 percent of the cohort fell into this highest category, meaning the statistical comparisons reflect a small segment of participants. These are rates observed in a cohort living ordinary lives, not the result of any assigned treatment.
Why the Stenosis Finding Carries More Weight Than the Plaque Finding
The difference between forming a new plaque and developing arterial stenosis represents two fundamentally distinct stages of vascular disease progression. The hazard ratio of 1.27 for initial plaque formation represents a relatively modest elevation in baseline risk. That modest figure means that possessing an Lp(a) level above 50 mg/dL did not guarantee rapid initial plaque development.
In contrast, the odds of progressing to 50 percent or greater stenosis once plaque already existed were more than doubled. The association was therefore stronger for how far plaque progressed than for whether it appeared at all.
The Suita Study data show higher Lp(a) levels tracking with more pronounced narrowing over time. An elevated marker describes a trajectory measured across a cohort, not a present state of blockage in any one person.
The absence of an exact odds ratio requires caution when interpreting the practical magnitude of this stenosis finding. We know only that the relative odds exceeded two, without data on the absolute event rates in each subgroup. That distinction matters when evaluating how much personal risk a specific biomarker value actually confers.
What an Observational Cohort Cannot Tell You
Observational cohort data demonstrate statistical correlations over time but cannot establish that lipoprotein(a) directly caused the observed arterial changes. The Suita Study observed participants living their ordinary lives without assigned interventions, dietary controls, or randomized therapeutic protocols. The published report does not clarify whether the study employed a prospective or retrospective design beyond biennial ultrasound tracking.
Multiple methodological boundaries limit the direct application of these results to individual clinical management. First, the investigation examined a single cohort of Japanese adults from the Suita Study. Applying these specific numerical hazard rates to populations outside East Asia involves an untested epidemiological assumption.
Second, the published summary leaves out essential statistical metrics that clinicians use to evaluate evidence quality. The source omits confidence intervals for all three main findings and provides no numeric data for intima-media thickness changes. Without published confidence intervals, outside researchers cannot confirm the precision or statistical reliability of the 1.27 hazard ratio.
Most importantly, observational tracking cannot prove that lowering Lp(a) would prevent plaque from forming or progressing to stenosis. As the study authors noted, further studies must determine whether emerging Lp(a)-lowering therapies can alter long-term arterial outcomes. Until clinical trials deliver those answers, these numbers remain descriptive associations rather than therapeutic targets.
What This Does Not Change About Testing Lp(a)
This longitudinal study does not alter standard clinical guidance regarding how often an individual should measure circulating lipoprotein(a) concentrations. Circulating Lp(a) is a genetically determined blood lipid that remains largely stable across an individual adult lifespan. Unlike a standard lipid panel, Lp(a) concentrations do not respond to diet or exercise.
Our comprehensive Lp(a) biomarker guide explains why clinical protocols generally recommend measuring this marker once as a baseline assessment. Searchers wondering about comparative particle dynamics can read our analysis of Lp(a) versus ApoB. For broader context on circulating atherogenic particles, our ApoB guide covers routine lipid particle quantification.
Learning that an Lp(a) result exceeds 50 mg/dL does not indicate an urgent need for biennial carotid ultrasound scans. Ultrasound surveillance in the Suita Study served an epidemiological research purpose rather than an individual screening protocol. Readers exploring overall risk evaluation strategies can examine our central biomarkers hub for clinical context.
What Would Change This Read
Several specific scientific disclosures would alter how we interpret the Suita Study findings on arterial disease progression. First, publication of complete statistical data would clarify the true precision of the reported relative risk numbers. Having access to published confidence intervals and the exact odds ratio for severe stenosis would establish clear numerical bounds.
Second, replication studies across diverse geographic cohorts would demonstrate whether these progression rates generalize outside East Asian populations. The Suita Study answered questions about Japanese adults because prior regional evidence regarding carotid disease progression had remained thin. Similar longitudinal tracking in other population groups would reveal whether baseline Lp(a) behaves identically across diverse backgrounds.
Third, randomized controlled trial results showing that lowering Lp(a) prevents cardiovascular events would fundamentally change this observational interpretation. The study authors stated that future research must confirm whether targeted lipid reduction slows atherosclerosis or reduces clinical events. A physician holding your full cardiovascular record is the right person to say what your own Lp(a) result means.
Sources
- European Journal of Preventive Cardiology — Teramoto M. et al., Suita Study analysis of Lp(a) and carotid atherosclerosis progression, 2026, DOI 10.1093/eurjpc/zwag443. Accessed October 9, 2026.
- MedicalXpress — "Elevated lipoprotein(a) is associated with the progression of carotid atherosclerosis", October 2026. Accessed October 9, 2026.
Frequently Asked Questions
What did the Suita Study find about Lp(a) and carotid plaque?
In 3,272 Japanese adults followed for a median of 11.5 years, participants with Lp(a) at or above 50 mg/dL had a multivariable-adjusted hazard ratio of 1.27 for developing new carotid plaque compared with those under 15 mg/dL. Among participants who developed plaque, the group with 50 mg/dL or higher had more than twice the odds of progressing to 50 percent or greater carotid stenosis. Their carotid intima-media thickness also thickened faster per year. The source did not publish confidence intervals or exact numeric values for the thickness and stenosis metrics.
Does a high Lp(a) cause carotid plaque?
The Suita Study does not establish that high Lp(a) causes carotid plaque. The research used an observational cohort design that tracked participants over time without clinical intervention or randomized assignment. The findings demonstrate an association between baseline Lp(a) concentrations and subsequent plaque progression. Observational studies cannot prove that the blood lipid directly caused the arterial lesions or the luminal narrowing.
Is 50 mg/dL a clinical cut-off for Lp(a)?
The 50 mg/dL threshold used in this report represents an analytical grouping chosen by the study researchers, not a universal clinical treatment cutoff. The Suita Study sorted participants into four specific research bands: under 15 mg/dL, 15 to 29 mg/dL, 30 to 49 mg/dL, and 50 mg/dL or above. About 5 percent of the cohort fell into the 50 mg/dL or above group. The study coverage does not define clinical treatment guidelines or diagnostic thresholds.
Does this study apply to people who are not East Asian?
The study evaluated 3,272 Japanese adults, and the coverage explicitly addresses data gaps in East Asian populations. Applying these specific risk estimates to other demographic or ethnic groups represents an unverified assumption. Replication studies in other cohorts are needed to confirm whether similar progression rates occur globally.
Does lowering Lp(a) slow plaque progression?
This study does not answer whether lowering Lp(a) slows plaque progression. Because the Suita Study was an observational analysis without therapeutic interventions, it tracked progression as it occurred in the cohort without any assigned therapy. The study authors explicitly stated that further studies are needed to determine whether emerging Lp(a)-lowering therapies can slow carotid atherosclerosis progression or prevent cardiovascular events.
This article provides general health information and does not constitute medical advice. Discuss any biomarker test results and cardiovascular risk assessments with a licensed clinician holding your full medical record.